Scientific Progress

Thanks to the rapid progress in science over the course of the last decades we are able to offer our ambitious products to customers worldwide.

TICEBA - Company - Scientific Progress - Picture 01TICEBA - Company - Scientific Progress - Picture 02

The 21st century will be a century of biology and medicine. Tissue engineering (reconstruction of tissue) will be one of the key technologies. This still fledgling branch of medicine is among others dealing with the reproduction of tissue and whole organs from adult stem cells.

These adult stem cells have a decisive repair function. They are able to replace defective cells and allow for the organ or cell structure to be able to again carry out its original function.

Tissue engineering aims at "repairing" body tissue and organs with the help of adult stem cells and to thereby re-establish their natural function or to maintain it over longer time periods than ever before.

It is TICEBA's aim to offer its customers the possibility to retrieve their own healthy stem cells whenever they are needed for this kind of healing process.

Clinical Trial - EB

The trial has been approved by the U.S. Food and Drug Administration (FDA) and the other respective competent national regulatory authorities and has recently been granted Orphan Drug Designation for the treatment of RDEB in the EU and the USA.

Clinical Trial - LSCD

For the international and FDA approved clinical trial for the limbal stem cell medicinal product LSC2 our daughter company RHEACELL recently received Orphan Drug Designation status in the EU for the treatment of limbal stem cell deficiency (LSCD) and Fast Track Designation in the USA. More information can be found HERE and HERE.

Clinical Trials

Our subsidiary RHEACELL is recruiting patients for further clinical trials in phase I/IIa with allogeneic ABCB5-positive (ABCB5+) mesenchymal stem cells for the indications chronic venous ulcers (CVU), diabetic foot ulcers (DFU), peripheral arterial occlusive disease (PAOD), epidermolysis bullosa (EB) and acute on chronic liver failure (ACLF) and with allogeneic ABCB5+ limbal stem cells for the indication limbal stem cell deficiency (LSCD). For more information click HERE.


In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).